Market Summary
USD28.26+1.48
Market Closed5.53%
GH Stock Price
GH RSI Chart
GH Valuation
GH Price/Sales (Trailing)
GH Profitability
GH Fundamentals
GH Revenue
GH Earnings
Price Action
52 Week Range
24.2077.72
(Low)(High)
Last 7 days
-7.3%
Last 30 days
-3.8%
Last 90 days
-35.1%
Trailing 12 Months
-45.1%
GH Financial Health
GH Investor Care
Peers (Alternatives to Guardant Health)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HCA | 70.6B | 60.2B | -4.86% | -6.89% | 12.5 | 1.17 | 2.52% | -18.88% |
LH | 19.6B | 14.9B | -11.65% | -18.57% | 15.35 | 1.32 | -7.72% | -46.20% |
DGX | 15.5B | 9.9B | -9.17% | -4.78% | 16.43 | 1.57 | -8.39% | -52.58% |
| MID-CAP | ||||||||
UHS | 8.8B | 13.4B | -20.72% | -21.03% | 13 | 0.66 | 5.99% | -31.87% |
EHC | 5.3B | 4.3B | -15.50% | -2.92% | 19.39 | 1.21 | 8.31% | -34.26% |
LHCG | 5.2B | 2.3B | 3.17% | 35.63% | 86.23 | 2.28 | 2.85% | -58.05% |
ENSG | 5.0B | 3.0B | -3.25% | 4.25% | 22.21 | 1.65 | 15.15% | 15.43% |
AMN | 3.6B | 5.2B | -10.88% | -15.90% | 8.03 | 0.68 | 31.60% | 35.63% |
GH | 2.9B | 449.5M | -3.81% | -45.08% | -4.43 | 6.45 | 20.31% | -70.12% |
AMED | 2.5B | 2.2B | -17.56% | -48.92% | 20.74 | 1.11 | 0.41% | -43.27% |
| SMALL-CAP | ||||||||
RDNT | 1.3B | 1.4B | 12.22% | 10.36% | 120.12 | 0.89 | 8.74% | -56.93% |
BKD | 524.3M | 2.8B | -3.12% | -59.80% | -2.2 | 0.19 | 2.43% | -140.13% |
ENZ | 58.0M | 98.8M | -21.26% | -67.11% | -2.18 | 0.59 | -14.50% | -605.55% |
XGN | 38.5M | 45.4M | -7.42% | -70.30% | -0.96 | 0.85 | -5.93% | -72.41% |
PMD | 33.4M | 26.0M | 7.45% | -10.59% | -16.54 | 1.28 | 9.09% | -588.38% |
Financials for Guardant Health
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 4.4% | 449,538,000 | 430,755,000 | 408,130,000 | 391,087,000 | 373,653,000 |
| S&GA Expenses | 7.9% | 299,828,000 | 278,004,000 | 247,862,000 | 221,975,000 | 191,881,000 |
| R&D Expenses | 9.9% | 373,807,000 | 340,250,000 | 311,201,000 | 289,470,000 | 263,221,000 |
| EBITDA | -11.4% | -614,910,000 | -551,958,000 | -501,772,000 | -374,508,000 | - |
| EBITDA Margin | -6.8% | -1.37 | -1.28 | -1.23 | -0.96 | - |
| Earnings Before Taxes | -11.4% | -653,449,000 | -586,417,000 | -531,968,000 | -400,474,000 | -384,470,000 |
| EBT Margin | -6.8% | -1.45 | -1.36 | -1.30 | -1.02 | - |
| Interest Expenses | 0.0% | 2,577,000 | 2,576,000 | 2,576,000 | 2,575,000 | 2,577,000 |
| Net Income | -11.5% | -654,588,000 | -586,965,000 | -532,497,000 | -400,640,000 | -384,770,000 |
| Net Income Margin | -6.9% | -1.46 | -1.36 | -1.30 | -1.02 | - |
| Free Cahsflow | 0.2% | -386,924,000 | -387,787,000 | -363,195,000 | -309,494,000 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | -5.4% | 1,610 | 1,702 | 1,854 | 2,130 | 2,204 |
| Current Assets | 5.4% | 1,192 | 1,131 | 1,037 | 1,113 | 1,114 |
| Cash Equivalents | -10.5% | 142 | 158 | 215 | 574 | 492 |
| Inventory | -18.2% | 52.00 | 63.00 | 60.00 | 37.00 | 31.00 |
| Net PPE | -0.1% | 168 | 168 | 163 | 151 | 124 |
| Goodwill | 0% | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| Liabilities | 1.0% | 1,550 | 1,535 | 1,535 | 1,597 | 1,559 |
| Current Liabilities | 10.3% | 193 | 175 | 168 | 229 | 195 |
| Shareholder's Equity | -63.9% | 60.00 | 167 | 319 | 533 | 645 |
| Retained Earnings | -9.2% | -1,662 | -1,522 | -1,360 | -1,131 | -1,007 |
| Additional Paid-In Capital | 1.5% | 1,742 | 1,716 | 1,704 | 1,682 | 1,658 |
| Accumulated Depreciation | 13.1% | 70.00 | 61.00 | 55.00 | - | - |
| Shares Outstanding | 0.2% | 103 | 102 | 102 | 102 | 102 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -4.7% | -309 | -295 | -270 | -221 | -209 |
| Share Based Compensation | -3.2% | 95.00 | 98.00 | 112 | 121 | 151 |
| Cashflow From Investing | 179.9% | 150 | -187 | -276 | -76.22 | -63.15 |
| Cashflow From Financing | -0.8% | -189 | -187 | -173 | 3.00 | -66.82 |
Risks for GH
What is the probability of a big loss on GH?
95.3%
Probability that Guardant Health stock will be more than 20% underwater in next one year
82.5%
Probability that Guardant Health stock will be more than 30% underwater in next one year.
54.5%
Probability that Guardant Health stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does GH drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Guardant Health was unfortunately bought at previous high price.
Drawdowns
Returns for GH
Cumulative Returns on GH
-27.7%
3-Year Cumulative Returns
Which funds bought or sold GH recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -0.05 | -290,384 | 296,616 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 20.2 | -693,000 | 1,071,000 | -% |
2023-02-28 | Voya Investment Management LLC | added | 4.35 | -33,437,000 | 37,298,000 | 0.05% |
2023-02-24 | NATIXIS | sold off | -100 | -1,354,000 | - | -% |
2023-02-24 | SRS Capital Advisors, Inc. | unchanged | - | -2,280 | 2,720 | -% |
2023-02-21 | Adalta Capital Management LLC | reduced | -18.2 | -3,234,000 | 2,278,000 | 1.61% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | reduced | -41.21 | -14,179 | 5,821 | -% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | -100 | -116,000 | - | -% |
2023-02-17 | TRUIST FINANCIAL CORP | reduced | -11.23 | -454,140 | 368,860 | -% |
2023-02-16 | HARBOUR INVESTMENTS, INC. | added | 2.65 | -5,413 | 11,587 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Guardant Health News
Schedule 13G FIlings of Guardant Health
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Mar 10, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 14, 2023 | viking global investors lp | 4.0% | 4,107,644 | SC 13G/A | |
| Feb 13, 2023 | capital international investors | 7.7% | 7,879,355 | SC 13G | |
| Feb 13, 2023 | capital research global investors | 2.0% | 2,001,782 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.83% | 9,040,240 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 5.4% | 5,495,293 | SC 13G | |
| Mar 09, 2022 | blackrock inc. | 4.9% | 4,961,865 | SC 13G/A | |
| Feb 11, 2022 | capital research global investors | 7.8% | 7,927,702 | SC 13G | |
| Feb 10, 2022 | fmr llc | - | 0 | SC 13G/A |
GH Fair Value
Guardant Health fair value in different scenarios
The table shows the Fair Value estimates for Guardant Health for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | - - | 0.48 -98.30% | 2.81 -90.06% | 7.07 -74.98% | 11.13 -60.62% |
| Current Inflation | 0.29 -98.97% | 0.34 -98.80% | 2.36 -91.65% | 6.02 -78.70% | 9.49 -66.42% |
| Very High Inflation | - - | 0.17 -99.40% | 1.84 -93.49% | 4.79 -83.05% | 7.59 -73.14% |
Historical Guardant Health Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Guardant Health
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 16, 2023 | 4 | Insider Trading | |
| Mar 16, 2023 | 4 | Insider Trading | |
| Mar 16, 2023 | 4 | Insider Trading | |
| Mar 15, 2023 | 4 | Insider Trading | |
| Mar 13, 2023 | 8-K | Current Report | |
| Mar 10, 2023 | SC 13G/A | Major Ownership Report | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Mar 03, 2023 | 4 | Insider Trading | |
| Mar 03, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for GH
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-14 | Talasaz AmirAli | bought | 112,188 | 26.3972 | 4,250 | co-chief executive officer |
2023-03-14 | Talasaz AmirAli | bought | 224,376 | 26.3972 | 8,500 | co-chief executive officer |
2023-03-13 | Talasaz AmirAli | bought | 513,107 | 25.6554 | 20,000 | co-chief executive officer |
2023-03-13 | Talasaz AmirAli | bought | 1,026,220 | 25.6554 | 40,000 | co-chief executive officer |
2023-03-04 | Joyce Meghan V. | acquired | - | - | 66.00 | - |
2023-03-03 | Kalia Kumud | sold | -207,466 | 31.9179 | -6,500 | chief information officer |
2023-03-01 | Saia John G. | acquired | - | - | 263 | chief legal officer |
2023-03-01 | Kalia Kumud | sold (taxes) | -7,222 | 29.36 | -246 | chief information officer |
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
GH Income Statement
2022-12-31Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Revenue: | |||
| Precision oncology testing | $ 392,049 | $ 304,312 | $ 236,324 |
| Development services and other | 57,489 | 69,341 | 50,406 |
| Total revenue | 449,538 | 373,653 | 286,730 |
| Costs and operating expenses: | |||
| Cost of precision oncology testing | 148,199 | 110,396 | 74,769 |
| Cost of development services and other | 8,126 | 12,516 | 17,766 |
| Research and development expense | 373,807 | 263,221 | 149,862 |
| Sales and marketing expense | 299,828 | 191,881 | 106,513 |
| General and administrative expense | 163,956 | 206,640 | 192,770 |
| Total costs and operating expenses | 993,916 | 784,654 | 541,680 |
| Loss from operations | (544,378) | (411,001) | (254,950) |
| Interest income | 6,069 | 3,930 | 10,171 |
| Interest expense | (2,577) | (2,577) | (4,766) |
| Other income (expense), net | (12,778) | 25,178 | 3,641 |
| Fair value adjustments of noncontrolling interest liability | (99,785) | 0 | 0 |
| Loss before provision for income taxes | (653,449) | (384,470) | (245,904) |
| Provision for income taxes | 1,139 | 300 | 379 |
| Net loss | (654,588) | (384,770) | (246,283) |
| Adjustment of redeemable noncontrolling interest | 0 | (20,900) | (7,500) |
| Net loss attributable to Guardant Health, Inc. common stockholders - basic | (654,588) | (405,670) | (253,783) |
| Net loss attributable to Guardant Health, Inc. common stockholders - diluted | $ (654,588) | $ (405,670) | $ (253,783) |
| Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share) | $ (6.41) | $ (4.00) | $ (2.60) |
| Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share) | $ (6.41) | $ (4.00) | $ (2.60) |
| Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares) | 102,178 | 101,314 | 97,504 |
| Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares) | 102,178 | 101,314 | 97,504 |
GH Balance Sheet
2022-12-31Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 | ||
|---|---|---|---|---|
| Current assets: | ||||
| Cash and cash equivalents | $ 141,647 | $ 492,202 | ||
| Short-term marketable debt securities | 869,584 | 440,546 | ||
| Accounts receivable, net | 97,256 | 97,652 | ||
| Inventory, net | 51,598 | 30,674 | ||
| Prepaid expenses and other current assets, net | 31,509 | 53,052 | ||
| Total current assets | 1,191,594 | 1,114,126 | ||
| Long-term marketable debt securities | 0 | 698,034 | ||
| Property and equipment, net | 167,920 | 124,461 | ||
| Right-of-use assets, net | 174,001 | 189,443 | ||
| Intangible assets, net | 11,727 | 14,207 | ||
| Goodwill | 3,290 | 3,290 | ||
| Other assets, net | 61,453 | 60,938 | ||
| Total Assets | [1] | 1,609,985 | 2,204,499 | |
| Current liabilities: | ||||
| Accounts payable and accrued liabilities | 175,817 | 105,361 | ||
| Noncontrolling interest liability | 0 | 78,000 | ||
| Deferred revenue | 17,403 | 11,326 | ||
| Total current liabilities | 193,220 | 194,687 | ||
| Convertible senior notes, net | 1,137,391 | 1,134,821 | ||
| Long-term operating lease liabilities | 210,015 | 226,053 | ||
| Other long-term liabilities | 9,179 | 3,933 | ||
| Total Liabilities | [1] | 1,549,805 | 1,559,494 | |
| Commitments and contingencies (Note 10) | ||||
| Stockholders’ equity: | ||||
| Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2022 and 2021 | 0 | 0 | ||
| Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of December 31, 2022 and 2021; 102,619,383 and 101,767,446 shares issued and outstanding as of December 31, 2022 and 2021, respectively | 1 | 1 | ||
| Additional paid-in capital | 1,742,114 | 1,657,593 | ||
| Accumulated other comprehensive loss | (19,522) | (4,764) | ||
| Accumulated deficit | (1,662,413) | (1,007,825) | ||
| Total Stockholders’ Equity | 60,180 | 645,005 | ||
| Total Liabilities and Stockholders’ Equity | $ 1,609,985 | $ 2,204,499 | ||
| ||||